Sarcopenia predicts reduced liver growth and reduced resectability in patients undergoing portal vein embolization before liver resection - A DRAGON collaborative analysis of 306 patients
Jan Heil(University Hospital Ulm), Erik Schadde(Edinburgh Royal Infirmary), Abrar Nawawi(McGill University Health Centre), Ulrik Carling(Oslo University Hospital), Per Sandström(Linköping University), Ernesto Sparrelid(Karolinska University Hospital), Andreas A. Schnitzbauer(American Institute of Biological Sciences), Peter Metrakos(McGill University Health Centre), Pim B. Olthof(Erasmus MC), Wolf O. Bechstein(Unknown), Yannick Meyer(Erasmus MC Cancer Institute), Torkel B. Brismar(Karolinska University Hospital), Bergþór Björnsson(Linköping University), Joris I. Erdmann(Amsterdam University Medical Centers), Renato A. Hana(Montreal General Hospital), Dirk J. Grünhagen(Erasmus MC), Åsmund Avdem Fretland(University of Oslo), F. Heid(ZHAW Zurich University of Applied Sciences), Cornelis Verhoef(Erasmus MC Cancer Institute), Richard Linke(Goethe University Frankfurt), Joachim Hohmann(University Hospital of Basel)
Cited by 10
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
Right Portal Vein Ligation Combined With In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings
|Annals of Surgery|2012|1.3k
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
|The Lancet Oncology|2009|960
Immediate and long-term impact of the COVID-19 pandemic on delivery of surgical services
|British journal of surgery|2020|719